Imad Mansoor, MD
Internal Medicine · Bloomfield Hills, MINPI 1699883082
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 364 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 364 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$979
- GSK$587
- AstraZeneca$553
- Pfizer$537
- Amgen$503
- Lilly USA, LLC$403
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,346100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 90 | $979 |
| GSK | 46 | $587 |
| AstraZeneca(2 entities) | 33 | $553 |
| Pfizer | 37 | $537 |
| Amgen | 27 | $503 |
| Lilly USA, LLC | 25 | $403 |
| Sanofi-aventis U.S. LLC | 11 | $171 |
| Exact Sciences | 8 | $149 |
| Merck | 14 | $131 |
| AbbVie(2 entities) | 8 | $129 |
| Dexcom, Inc. | 6 | $127 |
| Corcept Therapeutics | 5 | $126 |
| Astellas Pharma US Inc | 7 | $105 |
| Boehringer Ingelheim | 6 | $101 |
| Abbott | 5 | $91 |
| Amarin Pharma, Inc. | 5 | $70 |
| Novartis | 3 | $57 |
| Averitas Pharma Inc. | 2 | $47 |
| Bayer | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 3 | $40 |
| Inspire Medical Systems, Inc. | 1 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Cequr Corporation | 2 | $33 |
| Nevro Corp. | 1 | $27 |
| Sequel Med Tech, LLC | 1 | $26 |
| Mannkind Corporation | 1 | $25 |
| BD | 1 | $22 |
| Pulmonx Corporation | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Cashflow Solutions, LLC | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$5,346 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $124,627 |
| JardianceEmpagliflozin | 74 | $111,597 |
| RybelsusSemaglutide | 34 | $85,378 |
| FarxigaDapagliflozin Propanediol | 71 | $68,466 |
| EliquisApixaban | 94 | $68,118 |
| TrulicityDulaglutide | 63 | $61,385 |
| JanuviaSitagliptin Phosphate | 37 | $53,178 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $39,425 |
| Repatha SureclickEvolocumab | 36 | $36,426 |
| MounjaroTirzepatide | 33 | $34,005 |
| CreonLipase/Protease/Amylase | 15 | $29,270 |
| XareltoRivaroxaban | 19 | $23,982 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $22,207 |
| EntrestoSacubitril/Valsartan | 22 | $19,525 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $11,095 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $979 | $210,005130 claims |
| Boehringer IngelheimJardiance | $101 | $111,59774 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $403 | $95,39096 claims |
| AstraZenecaFarxiga, Brilinta | $553 | $73,91982 claims |
| PfizerEliquis | $537 | $68,11894 claims |
| MerckJanuvia | $131 | $53,17837 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $587 | $50,52060 claims |
| AbbVieCreon, Linzess | $129 | $40,26027 claims |
| Johnson & JohnsonXarelto | $20 | $23,98219 claims |
| NovartisEntresto | $57 | $19,52522 claims |
| Sanofi-aventis U.S. LLCLantus | $171 | $6,34232 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $20 | $2,719228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Bloomfield Hills
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
- A FendrickAnn Arbor$347K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.